BlossomHill Therapeutics (BLSM) vs Evotec (EVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Evotec is the larger company by market cap ($469.1 million vs $461.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | EVO |
|---|---|---|
| Share price | $14.51 | $1.32 |
| Market cap | $461.20M | $469.11M |
| 1-day change | +0.69% | -8.97% |
| YTD return | — | -57.14% |
| 1-year return | — | -55.56% |
| 5-year return | — | -94.44% |
| EPS (TTM) | $-10.38 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $3.87 |
| 52-week low | $11.02 | $1.32 |
| Distance from 52-week high | -48.16% | -65.89% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +143.97% | +237.12% |
| Average volume | 193.15K | 109.16K |
| Shares outstanding | 31.78M | 355.39M |
| Employees | 69 | 4,379 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,379 employees
BLSM vs EVO FAQ
Which is bigger, BlossomHill Therapeutics or Evotec?
Evotec (EVO) is larger, with a market capitalization of $469.11M compared with $461.20M for BlossomHill Therapeutics (BLSM).
Are BlossomHill Therapeutics and Evotec in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.